Similar articles

• [New bone density conservation agents for osteoporosis under research and development: Ibandronate].

  Tanaka I, Hashimoto J, Oshima H. Tanaka I, et al. Nihon Rinsho. 2007 Nov 28;65 Suppl 9:426-32. Nihon Rinsho. 2007. PMID: 18161144 Review. Japanese. No abstract available.
• Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.

  Ringe JD, Dorst A, Faber H, Ibach K, Preuss J. Ringe JD, et al. Rheumatology (Oxford). 2003 Jun;42(6):743-9. doi: 10.1093/rheumatology/keg205. Epub 2003 Apr 16. Rheumatology (Oxford). 2003. PMID: 12730532 Clinical Trial.
• Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.

  Guay DR. Guay DR. Pharmacotherapy. 2006 May;26(5):655-73. doi: 10.1592/phco.26.5.655. Pharmacotherapy. 2006. PMID: 16637795 Review.
• Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.

  Nakamura T, Ito M, Hashimoto J, Shinomiya K, Asao Y, Katsumata K, Hagino H, Inoue T, Nakano T, Mizunuma H; MOVEST Study Group. Nakamura T, et al. Osteoporos Int. 2015 Nov;26(11):2685-93. doi: 10.1007/s00198-015-3175-1. Epub 2015 May 23. Osteoporos Int. 2015. PMID: 26001561 Free PMC article. Clinical Trial.
• Intravenous ibandronate (Boniva).

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2006 Aug 14-28;48(1241-1242):68-9. Med Lett Drugs Ther. 2006. PMID: 16977282 No abstract available.